Kyle A. Planck holds a Ph.D. in Pharmacology and has extensive experience in scientific research and writing. At MBHB, Dr. Planck provides technological advice toward validity, infringement, and patentability analyses in the biotechnology and pharmaceuticals area.

Prior to joining the firm, Dr. Planck pursued doctoral studies at Weill Cornell Medicine, specializing in infectious diseases microbiology, analytical biochemistry method development, and systems-level analysis of drug uptake and metabolism. This research, supported by an NIH F31 predoctoral fellowship, expanded understanding of bacterial physiology and laid the groundwork for further development of a novel class of small molecule inhibitors for the treatment of tuberculosis. In addition to his doctorate work, Dr. Planck has conducted research in medicinal chemistry at the University of Notre Dame, natural products chemistry at the University of California, San Diego, and protein production and purification at the Novartis Institutes for Biomedical Research. His work is underpinned by a zeal for accelerating biomedical innovations from the bench to the bedside, and his approach to client matters is informed by his experience throughout the drug development process in both academic and industry settings.

Outside of the office, Dr. Planck can be found biking along the lakeshore, spending time with his dog, or scouring Chicago in search of the best nitro cold brew.

• Wong AI, Beites T, Planck KA, Fieweger RA, Eckartt KA, Li S, Poulton NC, VanderVen BC, Rhee KY, Schnappinger D, Ehrt S, Rock J. Cyclic AMP is a critical mediator of intrinsic drug resistance and fatty acid metabolism in tuberculosis. eLife (2023). PMCID: PMC9995111.
• Pepi MJ, Chacko S, Marqus GM, Singh V, Wang Z, Planck K, Cullinane RT, Meka PN, Gollapalli DR, Ioerger TR, Rhee KY, Cuny GD, Boshoff HIM, Hedstrom L. A D-phenylalanine-benzoxazole derivative reveals the role of the essential enzyme Rv3603c in the pantothenate biosynthetic pathway of Mycobacterium tuberculosis. ACS Infectious Diseases (2022). PMCID: PMC9558617.
• London AS, Japutra C, Planck K, Lihon M, Nguyen AA. A novel method to determine residual detergent in biological samples post endotoxin reduction treatment and evaluation of strategies for subsequent detergent removal. International Immunopharmacology (2015).